Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee
Muscle & Nerve · 2023
DOI: 10.1002/mus.27922 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Muscle & Nerve, 2023. Verfasst von Jinny Tavee und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, Division of Neurology, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Dermatomyositis, Neuromuscular Diseases, Myasthenia Gravis, Guillain-Barre Syndrome. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 134 Literaturangaben.
Abstract (Originalsprache)
Intravenous immune globulin (IVIG) is an immune‐modulating biologic therapy that is increasingly being used in neuromuscular disorders despite the paucity of high‐quality evidence for various specific diseases. To address this, the AANEM created the 2009 consensus statement to provide guidance on the use of IVIG in neuromuscular disorders. Since then, there have been several randomized controlled trials for IVIG, a new FDA‐approved indication for dermatomyositis and a revised classification system for myositis, prompting the AANEM to convene an ad hoc panel to update the existing guidelines.New recommendations based on an updated systemic review of the literature were categorized as Class I‐IV. Based on Class I evidence, IVIG is recommended in the treatment of chronic inflammatory demyelinating polyneuropathy, Guillain‐Barré Syndrome (GBS) in adults, multifocal motor neuropathy, dermatomyositis, stiff‐person syndrome and myasthenia gravis exacerbations but not stable disease. Based on Class II evidence, IVIG is also recommended for Lambert‐Eaton myasthenic syndrome and pediatric GBS. In contrast, based on Class I evidence, IVIG is not recommended for inclusion body myositis, post‐polio syndrome, IgM paraproteinemic neuropathy and small fiber neuropathy that is idiopathic or associated with tri‐sulfated heparin disaccharide or fibroblast growth factor receptor‐3 autoantibodies. Although only Class IV evidence exists for IVIG use in necrotizing autoimmune myopathy, it should be considered for anti‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase myositis given the risk of long‐term disability. Insufficient evidence exists for the use of IVIG in Miller‐Fisher syndrome, IgG and IgA paraproteinemic neuropathy, autonomic neuropathy, chronic autoimmune neuropathy, polymyositis, idiopathic brachial plexopathy and diabetic lumbosacral radiculoplexopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Jewish Health, Division of Neurology, Denver, Colorado, USA.
- Vagelos College of Physicians and Surgeons, Neurological Institute, Columbia University, New York, New York, USA.
- Adirondack Neurology Associates, PC, Glens Falls, New York, USA.
- Stanford Neuroscience Health Center, Palo Alto, California, USA.
- National Jewish Health, Denver, Colorado, USA.
- Neurology Clinic, Vanderbilt University, Nashville, Tennessee, USA.
ORCID-Profile: Liz Kellermeyer
Zitieren
APA
Tavee, J., Brannagan, T. H., Lenihan, M. W., Muppidi, S., Kellermeyer, L., D Donofrio, P., & AANEM (2023). Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle & Nerve. https://doi.org/10.1002/mus.27922
Vancouver
Tavee J, Brannagan TH, Lenihan MW, Muppidi S, Kellermeyer L, D Donofrio P, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle & Nerve. 2023. doi:10.1002/mus.27922
BibTeX
@article{Tavee2023,
author = {Tavee, Jinny and Brannagan, Thomas H and Lenihan, Michael W and Muppidi, Sri and Kellermeyer, Liz and D Donofrio, Peter and AANEM, AANEM},
title = {Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee},
journal = {Muscle & Nerve},
year = {2023},
doi = {10.1002/mus.27922}
}
EUVIMED